Added to YB: 2026-05-19
Pitch date: 2026-05-15
NVO [neutral]
Novo Nordisk A/S
-2.54%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.3T
Pitch Price
DKK 295.00
Price Target
N/A
Dividend
3.91%
EV/EBITDA
8.27
P/E
10.92
EV/Sales
4.43
Sector
Pharmaceuticals
Category
growth
Show full summary:
Novo Nordisk A/S: Evolving Beyond Obesity
NVO (holding update): Not dead - 100yr insulin data + OpenAI partnership could unlock longevity platform beyond obesity. Semaglutide cuts inflammation 40-50%, targets $100B+ painkiller market. Only 3% obesity patients treated; 97% TAM untapped. Wegovy record scripts wk1. Author holds 9% portfolio weight.
Read full article (3 min)